 NEW YORK, Dec. 15, 2020 GLOBE NEWSWIRE -- Cellectis Euronext Growth: ALCLS - Nasdaq: CLLS, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells UCART, today announced that it has withdrawn the proposed underwritten offering of American Depositary Shares ADS due to market conditions. 